Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses the importance of device design for biosimilars.
Transcript:
I think device design is a super exciting area for innovation that biosimilars can actually bring to the marketplace, so especially for Sandoz, because we're part of a larger organization, we have access to some tremendous device technology that we can bring into the marketplace with already having had the experience, right? It's not like we have to start from scratch to create that innovation in terms of device, but we can actually benefit from all the innovation that's happened in the past from other manufacturers and bring that into our biologic products to make sure that patients get exactly what's easy.
I do think it's important. I think there's a big stigma associated with either sitting in an infusion chair for hours or sticking yourself with a needle every day. We see it in diabetes, right? You see it in arthritis now, and there's been some tremendous innovation in terms of those devices. So I think it's a pretty exciting area for us and certainly one that we're always looking for new and better ways to make it easier for patients to not only access their medication, pay for them, and also benefit from the innovations in terms of making it simple.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.